The Board of Zhaoke Ophthalmology Limited announced that the marketing authorization for Bimatoprost Timolol eye, a drug researched, developed and manufactured by the Company for the treatment of glaucoma, has been obtained from the National Medical Products Administration. This drug is used to lower the intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension who do not respond sufficiently to -blockers or prostaglandin analogues. Bimatoprost Timolol eye drop is the first generic drug of Bimatoprost Timolol eye drop for the treatment of glaucoma/ocular hypertension in China.

Manufactured on the production line that has been certified in a Good Manufacturing Practice compliance check, this product has already passed consistency evaluation. Bimatoprost Timolol eye drop is a drug combination that comprises Bimatoprost and Timolol maleate. It lowers IOP by using three mechanisms, namely increasing uveoscleral and trabecular outflow of aqueous humor as well as reducing the production of aqueous humor in the ciliary body.

It is more effective in lowering IOP and maintaining stable post-treatment IOP as compared with other drug combinations. Furthermore, the rate of Bimatoprost Timolol eye drop resulting in an adverse reaction, namely conjunctival hyperemia, is significantly lower than that of monotherapy /unfixed-dose combination. The marketing authorization for Bimatoprost Timolol eye drop marks a major milestone of the Company in the development of drug treatment for glaucoma and begins a new chapter in the Company's glaucoma franchise currently comprised of a total of seven drugs and one device for home use IOP measurement.

Being the first generic drug of the Company to be authorized by NMPA, Bimatoprost Timolol eye drop also signifies the commencement of the commercialization of the Company's pipeline products.